2021

Sacks NC, Healey BE, Cyr PL, Slocomb T, James E, Beggs AH, Graham RJ. 2021. Costs and health resource use in patients with X-linked myotubular myopathy: insights from U.S. commercial claims. J Manag Care Spec Pharm 27(8):1019–1026, DOI: 10.18553/jmcp.2021.20501, online article.

View Abstract

Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. 2021. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis. The Oncologist 26(9):e1609–e1618 (open access), https://doi.org/10.1002/onco.13822.

View Abstract

Rehorn M, Sacks NC, Emden MR, Healey B, Preib MT, Cyr PL, Pokorney SD. 2021. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol.

View Abstract

Chew D, Sacks NC, Emden MR, Preib MT, Cyr PL, Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 132–140.

View Abstract

Sheshadri A, Healey B, Sacks N, Wu E, Cyr P, Boerner G, Huang H. 2021. Bronchiolitis obliterans syndrome following lung transplantation: Economic burden by chronic lung allograft dysfunction (CLAD) stage. J Heart Lung Trans 40:4;S70.

Frankenfeld CL, Leslie TF, Menon NM. 2021. Longer time-to-treatment but better survival for colorectal cancer patients presumptively not diagnosed in a hospital. Cancer Causes Control 32:1185–1191.

View Abstract

Frankenfeld CL, Hakes JK, Leslie TF. 2021. All-cause mortality and residential racial and ethnic segregation and composition as experienced differently by individual-level race, ethnicity, and gender: Mortality Disparities in American Communities data. Ann Epidemiol 65:38-45, https://doi.org/10.1016/j.annepidem.2021.10.008.

View Abstract

2020

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198. doi: 10.14740/gr1167.

View Abstract

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp (open access).

View Abstract

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

View Abstract